exomind vs neurostar: Cost, Evidence, and Fit

What EXOMIND and NeuroStar Machines Cost

The acquisition cost is close enough to force a real operating-model decision. A new NeuroStar runs $80,000-$150,000 with used units at $40,000-$80,000, while EXOMIND lists at $100,000-$200,000 new Device Pulse comparison.

NeuroStar wins the capital-planning argument because there is a secondary market. A practice can buy used equipment, preserve cash, and enter TMS without committing to the upper end of a new-device quote. That option matters when the practice is still proving referral volume or building an in-house psychiatric service line.

EXOMIND is too new to offer the same escape hatch. Its limited secondary market means buyers should treat the purchase as a new-equipment decision. The device may earn back that investment through a shorter protocol, but the up-front commitment is harder to soften.

The patient-facing pricing picture is also uneven. NeuroStar per-session pricing runs $300-$500 (insurance reimbursable) while EXOMIND per-session pricing is still emerging Device Pulse comparison.

That “still emerging” language deserves attention. It does not mean EXOMIND cannot produce revenue. It means a practice has less market history to use when forecasting cash pay, payer acceptance, collection rates, and referral conversion. NeuroStar has spent years becoming legible to insurers, clinicians, and patients. EXOMIND has to earn that familiarity.

NeuroStar also carries recurring costs that belong in any purchase model. NeuroStar treatment cap consumables run $2,000-$5,000 per year with maintenance at $5,000-$10,000 Device Pulse comparison.

Those expenses are predictable, which is useful. Predictable costs let a practice model margins before the first patient starts treatment. EXOMIND’s consumable and per-session economics need more market history before they offer the same confidence.

A buyer focused on lowering initial capital exposure has a clear route with NeuroStar. A buyer willing to pay for a newer device and build the economics around shorter treatment courses may accept EXOMIND’s uncertainty.

The Side-by-Side Comparison

The table tells the story without much decoration. NeuroStar is built around familiarity. EXOMIND is built around compression.

That distinction affects who sells the service, how referral partners describe it, how the front desk talks about treatment, and how quickly a patient can see the full course through. It also affects what kind of risk the practice is taking.

NeuroStar’s risk is operational: can you fill a longer treatment schedule consistently? EXOMIND’s risk is market development: can you establish demand and pricing for a newer protocol?

For a deeper device-level review, see the NeuroStar review and EXOMIND review.

What EXOMIND Therapy Is

EXOMIND therapy is BTL Industries’ ExoTMS treatment platform. It uses a patented ExoTMS coil design to deliver transcranial magnetic stimulation externally, without surgery or implanted hardware. The practical point for a patient is straightforward: they come into the practice for a series of treatments aimed at depression.

TMS uses magnetic pulses to stimulate targeted parts of the brain. NeuroStar uses focused figure-8 coil technology. EXOMIND uses BTL’s proprietary coil design and describes the approach as ExoTMS. The names differ, but a searcher new to the category should understand that EXOMIND belongs in the standard noninvasive TMS conversation.

NeuroStar was the first FDA-cleared TMS system and is cleared for major depressive disorder, obsessive-compulsive disorder, and anxious depression. EXOMIND is cleared for depression in the United States. EXOMIND is also cleared in Canada and the European Union for anxiety, obsessive-compulsive disorder, and binge eating.

That broader international clearance picture may be interesting to practices that watch global treatment trends. It does not replace the need to evaluate the device based on the indications a practice can offer in its own market.

Patients tend to care less about the device’s internal naming and more about the treatment burden. How often do they need to come in? How long are they in the chair? What will insurance cover? How soon can they get through the course? EXOMIND’s appeal starts with that last question.

Clinicians have a different checklist. They need to assess clearance, evidence quality, patient selection, staffing requirements, referral expectations, payer behavior, and the treatment workflow. A shorter protocol can be attractive. It can also create more pressure to explain a newer option credibly to referral sources who know NeuroStar by name.

6 Sessions vs 36 Sessions: Protocol and Throughput Economics

EXOMIND is FDA-cleared for depression in just 6 sessions versus NeuroStar's standard 36 sessions over 9 weeks Device Pulse comparison.

This is the core commercial contrast.

A patient going through a NeuroStar course makes repeated visits over a longer span. That creates more touchpoints with the practice, more appointment volume, and a familiar cadence for clinics built around insurance reimbursement. It also creates friction. A patient needs the schedule, transportation, and persistence to complete a longer course.

EXOMIND concentrates treatment into a much shorter schedule. That can make the therapy easier to fit around work, caregiving, travel, and the ordinary mess of a patient’s week. A practice may also be able to turn treatment capacity over faster.

The throughput argument sounds simple until you put it against revenue. A shorter protocol frees capacity, but it also gives the practice fewer billable treatment encounters per patient. The economics depend on what the practice can charge, what payers recognize, how many new patients it can attract, and whether that freed capacity can be filled.

A clinic with a waitlist may see shorter courses as a capacity multiplier. A clinic still building a referral base may prefer the longer NeuroStar pathway because it creates a more established reimbursement and scheduling model. Neither answer is universal.

NeuroStar sessions run 19-37 minutes each Device Pulse comparison.

Session duration is only one part of staffing. Room turnover, intake, clinical oversight, documentation, scheduling, and payer administration all consume labor. Still, chair time shapes the daily rhythm of a TMS practice. A device purchase should include an honest map of how the protocol fits your rooms, staff, and referral pipeline.

A busy multi-provider clinic may value EXOMIND because it can complete courses quickly. A focused TMS program with strong payer relationships may value NeuroStar because the longer protocol sits inside a proven system. The best choice comes from matching the device to the bottleneck you already have.

Clinical Evidence: Registry Depth vs Emerging Data

NeuroStar was FDA cleared in 2008 and EXOMIND in 2024 Device Pulse comparison.

That gap shows up in the evidence base. NeuroStar has 100+ published studies and a 5M+ treatment outcomes registry Device Pulse comparison.

For a psychiatrist, registry depth has practical value. It gives the device a much larger body of real-world outcomes, clinician familiarity, and published material to discuss with colleagues, payers, and patients. NeuroStar’s evidence is the strongest in the category.

EXOMIND’s data are emerging. The full peer-reviewed evidence base is still developing, which leaves more room for clinical judgment and less room for claims built on years of registry experience. Early buyers are making a calculated bet that the shorter depression protocol will earn a place in the market before the evidence library reaches NeuroStar’s depth.

That does not make EXOMIND a weak device. It makes it a newer one. Those are different statements, and practice owners should keep them separate.

Some buyers want the device that already has the thickest stack of studies, outcomes, and payer familiarity. Others want to offer something newer before local competitors do. The second group has to be comfortable explaining why a short protocol belongs alongside established TMS treatment.

NeuroStar wins on evidence today. EXOMIND wins on novelty and treatment compression. The question is whether your referral partners value the first advantage more than your patients value the second.

Which Device Fits Your Practice?

NeuroStar is the safer pick for a practice that wants a mature TMS offering. Its strengths are clear: a long clinical record, a large outcomes registry, insurance-reimbursable session pricing, and a used-equipment market. It fits practices that want to plug TMS into an established clinical and financial model.

EXOMIND is the more aggressive choice. It asks a practice to accept a new-device price, emerging session economics, and a smaller evidence base in exchange for a treatment course that can be completed far faster. That can be compelling in markets where patient convenience and room capacity are the limiting factors.

The wrong way to make this decision is to treat the machine quote as the whole decision. Equipment price is only the entry ticket. The durable question is what the protocol does to patient acquisition, staffing, reimbursement, referrals, and daily scheduling.

If your practice already has referral partners who understand conventional TMS and insurers that pay for it, NeuroStar has the cleaner path. If your practice can market a short-course depression treatment and has the operational appetite to build demand around a new platform, EXOMIND offers a different kind of opening.

Practices comparing alternatives may also want to read BrainsWay Deep TMS vs EXOMIND. The market is getting more crowded, and the winner will not be the clinic with the most device logos on its website. It will be the clinic that can explain its treatment choice directly and deliver it consistently.

The Buyer Kit

Before signing either agreement, ask for the full commercial picture in writing: purchase price, financing terms, maintenance obligations, consumables, training, warranty coverage, software requirements, and implementation support.

Then pressure-test the protocol. Model the patient journey from referral to final session. Ask who will explain the treatment, who will schedule it, who will handle payer questions, and how the clinic will fill any capacity created by a shorter course.

For NeuroStar, focus on reimbursement assumptions and whether the longer schedule fits the clinic’s room capacity. For EXOMIND, focus on pricing assumptions, demand generation, and how the practice will present a newer treatment platform to patients and referral sources.

The device is only part of the purchase. The protocol becomes your operating model.